HIV+ vs HIV-: 7-day Point Prevalence Abstinence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.275 | 0.189 | 0.381 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.26 | 0.191 | 0.342 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0152 | -0.104 | 0.142 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.667 | 1.68 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.575 | 2.03 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on HIV+ than on HIV- | 66 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | HIV+ | HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment~Nicotine patch: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.~Behavioral counseling: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC). | 22 | 80 | OG000 | ClinicalTrials.gov |
| Group 2 | HIV- | HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test~Nicotine patch: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.~Behavioral counseling: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC). | 33 | 127 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | 7-day Point Prevalence Abstinence | ClinicalTrials.gov |
| Description | Smoking abstinence (primary outcome) will be assessed and biochemically verified at the End of Treatment Visit (week 12). The primary smoking outcome variable will be 7-day point prevalence abstinence (no smoking, not even a puff, for at least 7 days prior to the assessment) biochemically verified by carbon monoxide \< 5 ppm. | ClinicalTrials.gov |
| Time frame | End of Treatment (week 12) | ClinicalTrials.gov |
| Population | Only subjects who entered treatment following the two lab sessions were considered intent to treat and included in this analysis. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Cognition and Smoking Relapse (HCS) | ClinicalTrials.gov |
| NCT number | NCT03169101 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Smoking Cessation | ClinicalTrials.gov |
| Interventions | Nicotine patch, Behavioral counseling | ClinicalTrials.gov |
| Lead sponsor | University of Pennsylvania | ClinicalTrials.gov |
| Results first posted | 2024-05-10 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03169101?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.